Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]
PHASE2
The purpose of this study is to find out the effectiveness of pembrolizumab...
Status
Active Not Recruiting
Location
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
Can We Predict of the Response of High Risk Non Muscle Invasive Bladder Cancer Patients to Intravesical Bacillus Calmette-Guerin? The Role of Immunological Markers
NA
Intravesical BCG is the mainstay adjuvant management of high risk NMIBC. Ad...
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
PHASE3
The purpose of this study is to compare event-free survival (EFS) in partic...